| [1] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA cancer J Clin, 2011, 61(2):69-90.
|
| [2] |
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014 [J]. CA Cancer J Clin, 2014, 64(1): 9-29.
|
| [3] |
De GA, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J]. J Clin Oncol, 2000, 18(16): 2938-2947.
|
| [4] |
Goldberg RM, Daniel J, Sargent RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A north American intergroup trial [J]. J Clin Oncol, 2006, 24(21): 3347-3353.
|
| [5] |
Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study [J]. J Clin Oncol, 2004, 22(2): 229-237.
|
| [6] |
Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J]. The Lancet, 2000, 355(9209): 1041-1047.
|
| [7] |
Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26(12): 2006-2012.
|
| [8] |
Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J]. J Clin Oncol, 2004, 22(1): 23-30.
|
| [9] |
Kabbinavar FF, Hambleton J, Mass RD, et al. Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer [J]. Journal of Clinical Oncology, 2005, 23(16): 3706-3712.
|
| [10] |
Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phaseⅢstudy [J]. J Clin Oncol, 2008, 26(12): 2013-2019.
|
| [11] |
Heinemann V, Von-Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial[J]. The Lancet Oncology, 2014, 15(10): 1065-1075.
|
| [12] |
Pietrantonio F, Garassino MC, Torri V, et al. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306 [J]. Ann Oncol, 2012, 23(10): 2771-2772.
|
| [13] |
Koeberle D, Betticher DC, Von-Moos R, et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phaseⅢnon-inferiority trial (SAKK 41/06) [J]. Ann Oncol, 2015, 26(4): 709-714.
|
| [14] |
Yalcin S, Uslu R, Dane F, et al. Bevacizumab＋capecitabine as maintenance therapy after initial bevacizumab＋XELOX treatment in previously untreated patients with metastatic colorectal cancer: phaseⅢ'Stop and Go' study results--a Turkish Oncology Group Trial [J]. Oncology, 2013, 85(6): 328-335.
|
| [15] |
Diaz-Rubio E, Gomez-Espana A, Massuti B, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phaseⅢMACRO TTD study [J]. Oncologist, 2012, 17(1): 15-25.
|
| [16] |
Esin E, Yalcin S. Neuropathic cancer pain: What we are dealing with? How to manage it?[J]. Onco Targets Ther, 2014, 7: 599-618.
|
| [17] |
Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study [J]. J Clin Oncol, 2006, 24(3): 394-400.
|
| [18] |
Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study [J]. J Clin Oncol, 2009, 27(34): 5727-5733.
|
| [19] |
Wasan H, Meade AM, Adams R, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial [J]. The Lancet Oncology, 2014, 15(6): 631-639.
|
| [20] |
Hegewisch-Becker S, Graeven U, Lerchenmüller CA, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial [J]. The Lancet Oncology, 2015, 16(13): 1355-1369.
|
| [21] |
Simkens LHJ, Van-Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group [J]. The Lancet, 2015, 385(9980): 1843-1852.
|
| [22] |
Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial [J]. Lancet Oncol, 2011, 12(7): 642-653.
|
| [23] |
Xu RH, Shen L, Li J, et al. Expert consensus on maintenance treatment for metastatic colorectal cancer in China [J]. Chin J Cancer, 2016, 35(1): 13.
|
| [24] |
Waddell T, Gollins S, Soe W, et al. PhaseⅡstudy of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study [J]. Cancer Chemother Pharmacol, 2011, 67(5): 1111-1117.
|
| [25] |
Luo HY, Li YH, Wang W, et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety [J]. Ann Oncol, 2016, 27(6): 1074-1081.
|
| [26] |
Di-Bartolomeo M, Ciarlo A, Bertolini A, et al. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian trials of medical oncology phase Ⅱ study [J]. Eur J Cancer, 2015, 51(4): 473-481.
|
| [27] |
HagAlfonso PG, Benavides M, Ruiz AS, et al. PhaseⅡstudy of first-line mfolfox plus cetuximab (C) for 8 cycles followed by mfolfox plus C or single agent(S/A) C as maintenance therapy in patients (P) with metastatic colorectal cancer (mCRC): the MACRO-2 trial (Spanish Cooperative Group for the treatment of digestive tumors [TTD]) [R]. Ann Oncol, 2014, 25: iv168.
|
| [28] |
Hagman H, Frodin JE, Berglund A, et al. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial [J]. Ann Oncol, 2016, 27(1): 140-147.
|
| [29] |
Munoz A, Pericay C, Garcia-Giron C, et al. PhaseⅡstudy of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer [J]. Oncol Res, 2013, 21(4): 181-191.
|
| [30] |
Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial [J]. The Lancet Oncology, 2015, 16(15): 1493-1505.
|
| [31] |
Johnsson A, Hagman H, Frodin JE, et al. A randomized phase Ⅲ trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial [J]. Ann Oncol, 2013, 24(9): 2335-2341.
|
| [32] |
Xu W, Gong Y, Kuang M, et al. Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis [J]. Clin Drug Investig, 2017, 37(2): 155-165.
|
| [33] |
Alexander S, Djordje A, Bert H, et al. Upfront FOLFOXIRI＋bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer [J]. Br J Cancer, 2015,113(6): 872-877.
|